Abstract
“There is a growing body of evidence suggesting that wound healing in chronic diabetic foot ulcers is growth factor dependent, and that the therapeutic delivery of these growth factors to wounds topically, has the potential ability to accelerate wound healing in conjunction with conventional wound care”. There is, however, confusion about the utility of platelet rich plasma because the studies that have evaluated them use a wide range of products (different platelet and leukocyte concentrations, different techniques and frequencies of application, very heterogeneous simple, and different endpoints) making almost impossible to compare data and draw conclusions. In this study, we have analyzed the different platelet rich plasma products from a new perspective: cost-efficiency. According to our data, we observe that platelet rich plasma is a cost-effective option that allows faster healing of ulcers, and that should be taken into account in patients with long evolution ulcers.
Keywords: Cost-benefit analysis, skin ulcers, platelet-rich plasma, varicose ulcers.
Current Pharmaceutical Biotechnology
Title:Effectiveness and Efficiency of Platelet Rich Plasma in the Treatment of Diabetic Ulcers
Volume: 16 Issue: 7
Author(s): Raquel Cobos, Felipe Aizpuru, Naiara Parraza, Eduardo Anitua and Gorka Orive
Affiliation:
Keywords: Cost-benefit analysis, skin ulcers, platelet-rich plasma, varicose ulcers.
Abstract: “There is a growing body of evidence suggesting that wound healing in chronic diabetic foot ulcers is growth factor dependent, and that the therapeutic delivery of these growth factors to wounds topically, has the potential ability to accelerate wound healing in conjunction with conventional wound care”. There is, however, confusion about the utility of platelet rich plasma because the studies that have evaluated them use a wide range of products (different platelet and leukocyte concentrations, different techniques and frequencies of application, very heterogeneous simple, and different endpoints) making almost impossible to compare data and draw conclusions. In this study, we have analyzed the different platelet rich plasma products from a new perspective: cost-efficiency. According to our data, we observe that platelet rich plasma is a cost-effective option that allows faster healing of ulcers, and that should be taken into account in patients with long evolution ulcers.
Export Options
About this article
Cite this article as:
Cobos Raquel, Aizpuru Felipe, Parraza Naiara, Anitua Eduardo and Orive Gorka, Effectiveness and Efficiency of Platelet Rich Plasma in the Treatment of Diabetic Ulcers, Current Pharmaceutical Biotechnology 2015; 16 (7) . https://dx.doi.org/10.2174/138920101607150427111926
DOI https://dx.doi.org/10.2174/138920101607150427111926 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Understanding and Unknown Aspects of the Treatment of Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Opportunities for Future Studies
Current Rheumatology Reviews Meet Our Editorial Board Member:
Current Rheumatology Reviews Kidney Diseases and Chemokines
Current Drug Targets Nutraceuticals and their Novel Drug Delivery System: A Boon to Human Health
Current Nutrition & Food Science SANTAVAC ™: A Novel Universal Antigen Composition for Developing Cancer Vaccines
Recent Patents on Biotechnology ACE and ACE2 in Inflammation: A Tale of Two Enzymes
Inflammation & Allergy - Drug Targets (Discontinued) Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Current Medicinal Chemistry The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Current Drug Targets MRI of Central Nervous System (CNS) Vasculitis
Current Medical Imaging The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry Adverse Reactions Induced by Minocycline: A Review of Literature
Current Drug Safety The Paradoxical Reaction to Rituximab in Six Granulomatosis with Polyangiitis Patients: How Could it be Explained and Managed?
Current Rheumatology Reviews Testosterone as Potential Effective Therapy in Treatment of Obesity in Men with Testosterone Deficiency: A Review
Current Diabetes Reviews Modulation of Ion Channels in Pulmonary Arterial Hypertension
Current Pharmaceutical Design The Involvement of Norepinephrine in Behaviors Related to Psychostimulant Addiction
Current Neuropharmacology Local Activation and Systemic Dysregulation of T Lymphocytes in Sjögren’s Syndrome
Current Pharmaceutical Biotechnology 4’-Aminochalcones As Novel Inhibitors of the Chlorinating Activity of Myeloperoxidase
Current Medicinal Chemistry A Case of Pantoprazole Anaphylaxis with Cross Reactivity to All Proton Pump Inhibitors: Finding a Safe Alternative
Current Drug Safety Cytotoxic T Lymphocyte Antigen 4 Gene +49 A/G (rs231775) Polymorphism and Susceptibility to Systemic Lupus Erythematosus
Current Rheumatology Reviews A Review of the Diagnostic Scope of Biomarker Techniques, Genetic Screening and Virtual Scanning
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)